Martínez-Laguna, Daniel
Carbonell, Cristina
Bastida, José-Carlos
González, Milagros
Micó-Pérez, Rafael M.
Vargas, Francisco
Balcells-Oliver, Mónica
Canals, Laura
,
Funding for this research was provided by:
Amgen SA
Claire Desborough Amgen (Europe) GmbH
Article History
Received: 17 December 2021
Accepted: 2 June 2022
First Online: 15 July 2022
Declarations
:
: The study was approved by each ethics committee assigned to each center.
: Written or oral informed consent was obtained from all subjects before participating in this study.
: DML: personal fees from Amgen, Lilly, Rubió, Gedeon Richter, Pierre Fabre, Grünenthal, Theramex, and Italfarmaco; JCB: personal fees from AstraZeneca, Esteve, Boehringer Ingelheim, Bayer, Abbott, Almirall, Amgen, Chiessi, FAES, Grunenthal, GSK, Lilly, Menarini, MSD, Pfizer, Recordatti, Rovi, and Servier; MG: personal fees from Amgen, Stada, Rubió, and Grünenthal; RMP: fees from Amgen, UCB, Stada, Angelini, and Gebro; FV: personal fees from Pfizer, Grünenthal, MSD, Amgen, GSK, Lilly, Bristol-Myers Squibb, Servier, P&G Pharmaceuticals, Novartis, Almirall, Sanofi, and Mundipharma; MB and LC: Amgen employees.